Lazard Life Sciences Conference In Brief
This article was originally published in The Gray Sheet
Executive Summary
St. Jude nabs ANS: Stock symbol ANSI pulled off the NASDAQ after St. Jude successfully acquires all outstanding shares of the neuromodulation firm, CFO John Heinmiller announces Nov. 30 at the Lazard Life Sciences Conference in New York. The firm made the $1.3 bil. acquisition offer in October to leverage its expertise in low-voltage cardiac stimulation with ANS' knowledge of spinal cord stimulation (1"The Gray Sheet" Oct. 24, 2005, p. 16). During the conference, Heinmiller said that St. Jude plans to heavily market its Atlas and Epic ICD lines to gain market share in Japan; the products launched in September. "That's about a $125 mil.-$150 mil. market that we can just begin to participate in," he said, noting that the firm's pacemakers enjoy a 25%-28% market share in Japan...
You may also be interested in...
Cyberonics Could Be Acquisition Target With Permanent CEO Slot Left Open
Cyberonics' recent ouster of CEO Robert "Skip" Cummins could make the neurostimulation device firm an acquisition candidate for other implantable pulse generator manufacturers such as Medtronic or St. Jude Medical - both of which have made unsuccessful merger offers in the past
Cyberonics Could Be Acquisition Target With Permanent CEO Slot Left Open
Cyberonics' recent ouster of CEO Robert "Skip" Cummins could make the neurostimulation device firm an acquisition candidate for other implantable pulse generator manufacturers such as Medtronic or St. Jude Medical - both of which have made unsuccessful merger offers in the past
Senate Drafts Additional Bills To Regulate GPOs; MDMA Plans For ’06
The Senate Judiciary/Antitrust Subcommittee will consider two new legislative proposals it has drafted for regulating group purchasing organization (GPO) practices at a hearing likely to be held in February